Los Angeles Capital Management & Equity Research Inc. increased its position in Johnson & Johnson (NYSE:JNJ) by 0.7% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,012,879 shares of the company’s stock after acquiring an additional 6,629 shares during the period. Johnson & Johnson makes up about 0.7% of Los Angeles Capital Management & Equity Research Inc.’s portfolio, making the stock its 16th biggest holding. Los Angeles Capital Management & Equity Research Inc.’s holdings in Johnson & Johnson were worth $122,903,000 at the end of the most recent reporting period.

Other hedge funds have also recently modified their holdings of the company. SFE Investment Counsel raised its stake in shares of Johnson & Johnson by 1.8% during the 2nd quarter. SFE Investment Counsel now owns 22,110 shares of the company’s stock valued at $2,683,000 after buying an additional 383 shares during the last quarter. Gardner Russo & Gardner LLC raised its stake in shares of Johnson & Johnson by 30.4% during the 1st quarter. Gardner Russo & Gardner LLC now owns 1,715 shares of the company’s stock valued at $220,000 after buying an additional 400 shares during the last quarter. Diamant Asset Management Inc. raised its stake in shares of Johnson & Johnson by 1.3% during the 2nd quarter. Diamant Asset Management Inc. now owns 31,130 shares of the company’s stock valued at $3,777,000 after buying an additional 400 shares during the last quarter. Spectrum Management Group Inc. raised its stake in shares of Johnson & Johnson by 2.8% during the 1st quarter. Spectrum Management Group Inc. now owns 14,841 shares of the company’s stock valued at $1,902,000 after buying an additional 410 shares during the last quarter. Finally, Southeast Asset Advisors Inc. raised its stake in shares of Johnson & Johnson by 0.7% during the 1st quarter. Southeast Asset Advisors Inc. now owns 60,947 shares of the company’s stock valued at $7,810,000 after buying an additional 418 shares during the last quarter. Institutional investors own 66.60% of the company’s stock.

NYSE:JNJ opened at $145.34 on Friday. Johnson & Johnson has a 52 week low of $118.62 and a 52 week high of $148.32. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.72. The stock has a market cap of $388.35 billion, a PE ratio of 18.21, a price-to-earnings-growth ratio of 2.26 and a beta of 0.58.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Tuesday, October 16th. The company reported $2.05 EPS for the quarter, beating the Zacks’ consensus estimate of $2.03 by $0.02. Johnson & Johnson had a return on equity of 34.62% and a net margin of 1.89%. The firm had revenue of $20.35 billion for the quarter, compared to analysts’ expectations of $20.05 billion. During the same period last year, the firm earned $1.90 EPS. The company’s quarterly revenue was up 3.6% on a year-over-year basis. As a group, analysts expect that Johnson & Johnson will post 8.16 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Investors of record on Tuesday, November 27th will be issued a $0.90 dividend. This represents a $3.60 annualized dividend and a yield of 2.48%. The ex-dividend date is Monday, November 26th. Johnson & Johnson’s payout ratio is 49.32%.

In related news, insider Joaquin Duato sold 40,000 shares of Johnson & Johnson stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $144.36, for a total value of $5,774,400.00. Following the sale, the insider now directly owns 112,848 shares in the company, valued at approximately $16,290,737.28. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, COO Michael E. Sneed sold 29,000 shares of Johnson & Johnson stock in a transaction dated Monday, August 27th. The stock was sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now owns 59,124 shares in the company, valued at $7,969,915.20. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,340 shares of company stock worth $11,992,396. 0.22% of the stock is currently owned by insiders.

A number of equities analysts have weighed in on JNJ shares. Jefferies Financial Group set a $145.00 price objective on Johnson & Johnson and gave the company a “buy” rating in a research note on Sunday, July 15th. Credit Suisse Group set a $151.00 target price on Johnson & Johnson and gave the company a “buy” rating in a research report on Friday, July 13th. HC Wainwright restated a “buy” rating on shares of Johnson & Johnson in a research report on Wednesday, October 17th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research report on Saturday, July 28th. Finally, Citigroup raised their target price on Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a research report on Monday, October 22nd. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $142.54.

ILLEGAL ACTIVITY NOTICE: “Los Angeles Capital Management & Equity Research Inc. Has $122.90 Million Stake in Johnson & Johnson (JNJ)” was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another website, it was stolen and reposted in violation of US & international copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/11/10/los-angeles-capital-management-equity-research-inc-has-122-90-million-stake-in-johnson-johnson-jnj.html.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Read More: Earnings Per Share

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.